Longeveron
Life Science & Technology Park
1951 NW 7th Avenue, Suite 300
Miami
Florida
33136
United States
Tel: 305-342-9590
Website: http://www.longeveron.com/
About Longeveron
Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CSO: Joshua M. Hare, M.D.
144 articles about Longeveron
-
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
8/29/2023
Longeveron Inc. announced that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.
-
Longeveron Rights Offering Subscription Period Begins
8/22/2023
Longeveron Inc. announced that the subscription period for its previously announced rights offering has begun.
-
Longeveron Rights Offering Declared Effective and Calendar Finalized - August 16, 2023
8/16/2023
Longeveron Inc. announced that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar.
-
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
8/14/2023
Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET.
-
Longeveron Announces Pricing for Rights Offering and Expected Calendar
8/14/2023
Longeveron Inc. announced that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock.
-
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
8/11/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update.
-
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
8/11/2023
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) announced today the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) and using the Company’s Lomecel-B™ asset in Hypoplastic Left Heart Syndrome (HLHS), has surpassed the 50% enrollment threshold.
-
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
8/7/2023
Longeveron Inc. announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023.
-
Longeveron Appoints Lisa Locklear as Chief Financial Officer
7/20/2023
Longeveron Inc. announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer.
-
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical OfficerExperienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs
7/11/2023
Longeveron Inc. announced today the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer (CMO), effective as of July 1, 2023.
-
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
7/10/2023
Longeveron Inc. announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigious National Academy of Inventors (NAI) in recognition of his leading-edge research and development of stem cell therapies for heart disease.
-
Longeveron Files Registration Statement for Rights Offering
6/27/2023
Longeveron Inc. announced that it has filed a registration statement with the Securities and Exchange Commission to conduct a tradeable subscription rights offering to its shareholders and holders of warrants to purchase common stock as of a future record date to be determined.
-
Longeveron Welcomes Three New Prominent Board Members - June 13, 2023
6/13/2023
Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced the election of three distinguished new directors to serve on the Longeveron Inc. Board of Directors.
-
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
5/12/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the first quarter ended March 31, 2023.
-
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
5/9/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced new long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
-
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023Live conference call on Friday, May 12 at 8:30 a.m. ET
5/8/2023
Longeveron Inc. today announced that the Company will release its first quarter 2023 financial results on Friday, May 12, 2023 before the open of the U.S. financial markets.
-
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
4/19/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the first patient has been treated with Lomecel-B™ in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan.
-
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
3/10/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022.
-
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
3/6/2023
Longeveron Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets.
-
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
2/28/2023
Longeveron Inc. today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer.